Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. 2005

Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
St. Jude Children's Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA.

To elucidate interpatient variability in thioguanine nucleotide (TGN) concentrations in acute lymphoblastic leukemia (ALL) cells, we determined the TGN concentrations in leukemic blasts from 82 children with newly diagnosed ALL after intravenous administration of mercaptopurine (MP). Patients treated with MP alone achieved higher TGN concentrations than those treated with the combination of methotrexate plus mercaptopurine (MTX + MP). Analysis of the expression of approximately 9600 genes in ALL cells obtained at diagnosis identified 60 gene probes significantly associated with TGN accumulation in patients treated with MP alone and 75 gene probes in patients treated with MTX + MP, with no overlap between the 2 sets of genes. Genes significantly associated with intracellular TGN accumulation after MP alone included those encoding MP metabolic enzymes and transporters (eg, SLC29A1). Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside (NBMPR) caused a 33% to 45% reduction of TGN in ALL cells in vitro (P < .006), consistent with the gene expression findings. Genes associated with TGN concentration after combination therapy included those involved in protein and adenosine triphosphate (ATP)-biosynthesis. Together, these in vivo and in vitro data provide new insight into the genomic basis of interpatient differences in intracellular TGN accumulation and reveal significant differences between treatment with MP alone and treatment with MP and MTX.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D010802 Phylogeny The relationships of groups of organisms as reflected by their genetic makeup. Community Phylogenetics,Molecular Phylogenetics,Phylogenetic Analyses,Phylogenetic Analysis,Phylogenetic Clustering,Phylogenetic Comparative Analysis,Phylogenetic Comparative Methods,Phylogenetic Distance,Phylogenetic Generalized Least Squares,Phylogenetic Groups,Phylogenetic Incongruence,Phylogenetic Inference,Phylogenetic Networks,Phylogenetic Reconstruction,Phylogenetic Relatedness,Phylogenetic Relationships,Phylogenetic Signal,Phylogenetic Structure,Phylogenetic Tree,Phylogenetic Trees,Phylogenomics,Analyse, Phylogenetic,Analysis, Phylogenetic,Analysis, Phylogenetic Comparative,Clustering, Phylogenetic,Community Phylogenetic,Comparative Analysis, Phylogenetic,Comparative Method, Phylogenetic,Distance, Phylogenetic,Group, Phylogenetic,Incongruence, Phylogenetic,Inference, Phylogenetic,Method, Phylogenetic Comparative,Molecular Phylogenetic,Network, Phylogenetic,Phylogenetic Analyse,Phylogenetic Clusterings,Phylogenetic Comparative Analyses,Phylogenetic Comparative Method,Phylogenetic Distances,Phylogenetic Group,Phylogenetic Incongruences,Phylogenetic Inferences,Phylogenetic Network,Phylogenetic Reconstructions,Phylogenetic Relatednesses,Phylogenetic Relationship,Phylogenetic Signals,Phylogenetic Structures,Phylogenetic, Community,Phylogenetic, Molecular,Phylogenies,Phylogenomic,Reconstruction, Phylogenetic,Relatedness, Phylogenetic,Relationship, Phylogenetic,Signal, Phylogenetic,Structure, Phylogenetic,Tree, Phylogenetic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006150 Guanine Nucleotides Guanine Nucleotide,Guanosine Phosphates,Nucleotide, Guanine,Nucleotides, Guanine,Phosphates, Guanosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013873 Thionucleotides Nucleotides in which the base moiety is substituted with one or more sulfur atoms.
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H

Related Publications

Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
November 1994, Leukemia research,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
November 1994, Leukemia research,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
February 2002, Leukemia,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
September 2012, European journal of clinical pharmacology,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
June 2003, Clinical pharmacology and therapeutics,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
January 2021, PloS one,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
January 1998, Cancer chemotherapy and pharmacology,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
April 2020, Pediatric hematology and oncology,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
January 1989, Medical and pediatric oncology,
Gianluigi Zaza, and Meyling Cheok, and Wenjian Yang, and John C Panetta, and Ching-Hon Pui, and Mary V Relling, and William E Evans
May 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!